Filter by patients with: All

What is Laquinimod?

Category: Others

false

Laquinimod is an immunomodulator currently under development in phase III trials for treatment of multiple sclerosis as an oral therapy, like fingolimod. It has been shown to reduce disease activity on magnetic resonance imaging and to be well tolerated orally.

See patients taking Laquinimod

Reported purpose & perceived effectiveness
Purpose Patients Evaluations Perceived Effectiveness
Multiple sclerosis 5 2
  • Major
  • Moderate
  • Slight
  • None
  • Can't tell
See all 16 patients that have used Laquinimod

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations Percentage
Severe 0
Moderate 0
Mild 0
None 2

Commonly reported side effects and conditions associated with Laquinimod

Side effect Patients Percentage

Why patients stopped taking Laquinimod

Multiple reasons could be selected

Reason Patients Percentage
Did not seem to work 1
Other 1
See all 2 patients who've stopped using Laquinimod

Duration

Stopped using Laquinimod

Duration Patients Percentage
1 - 2 years 1
2 - 5 years 1
Adherence
Adherence Evaluations Percentage
Always 2
Usually 0
Sometimes 0
Never taken as prescribed 0
Burden
Burden Evaluations Percentage
Very hard to take 0
Somewhat hard to take 0
A little hard to take 0
Not at all hard to take 2
Cost per month
Cost per month Evaluations Percentage
$200+ 0
$100-199 0
$50-99 0
$25-49 0
< $25 2
Not specified 0

What people switch to and from

Patients started using Laquinimod after stopping:

Treatment Patients Percentage
Natalizumab (Tysabri) 1

Patients stopped using Laquinimod and switched to:

Treatment Patients Percentage
Natalizumab (Tysabri) 1
Last updated:
There are no evaluations for Laquinimod.